University of Kentucky HealthCare, Lexington, USA.
Massachusetts General Hospital, Boston, USA.
Neurocrit Care. 2021 Aug;35(1):39-45. doi: 10.1007/s12028-020-01137-5. Epub 2020 Nov 4.
BACKGROUND/OBJECTIVE: Stress-related mucosal bleeding (SRMB) occurs in approximately 2-4% of critically ill patients. Patients with aneurysmal subarachnoid hemorrhage (aSAH) have a (diffuse) space-occupying lesion, are critically ill, often require mechanical ventilation, and frequently receive anticoagulation or antiplatelet therapy after aneurysm embolization, all of which may be risk factors for SRMB. However, no studies have evaluated SRMB in patients with aSAH. Aims of the study were to determine the incidence of SRMB in aSAH patients, evaluate the effect of acid suppression on SRMB, and identify specific risk factors for SRMB.
This was a multicenter, retrospective, observational study conducted across 17 centers. Each center reviewed up to 50 of the most recent cases of aSAH. Patients with length of stay (LOS) < 48 h or active GI bleeding on admission were excluded. Variables related to demographics, aSAH severity, gastrointestinal (GI) bleeding, provision of SRMB prophylaxis, adverse events, intensive care unit (ICU), and hospital LOS were collected for the first 21 days of admission or until hospital discharge, whichever came first. Descriptive statistics were used to analyze the data. A multivariate logistic regression modeling was utilized to examine the relationship between specific risk factors and the incidence of clinically important GI bleeding in patients with aSAH.
A total of 627 patients were included. The overall incidence of clinically important GI bleeding was 4.9%. Of the patients with clinically important GI bleeding, 19 (61%) received pharmacologic prophylaxis prior to evidence of GI bleeding, while 12 (39%) were not on pharmacologic prophylaxis at the onset of GI bleeding. Patients who received an acid suppressant agent were less likely to experience GI bleeding than patients who did not receive pharmacologic prophylaxis prior to evidence of bleeding (OR 0.39, 95% CI 0.18-0.83). The multivariate regression analysis identified any instance of elevated intracranial pressure, creatinine clearance < 60 ml/min and the incidence of cerebral vasospasm as specific risk factors associated with GI bleeding. Cerebral vasospasm has not previously been described as a risk for GI bleeding (OR 2.5 95% CI 1.09-5.79).
Clinically important GI bleeding occurred in 4.9% of patients with aSAH, similar to the general critical care population. Risk factors associated with GI bleeding were prolonged mechanical ventilation (> 48 h), creatinine clearance < 60 ml/min, presence of coagulopathy, elevation of intracranial pressure, and cerebral vasospasm. Further prospective research is needed to confirm this observation within this patient population.
背景/目的:应激性黏膜出血(SRMB)在大约 2-4%的重症患者中发生。患有颅内动脉瘤性蛛网膜下腔出血(aSAH)的患者存在弥漫性占位性病变,病情危重,经常需要机械通气,并且在动脉瘤栓塞后经常接受抗凝或抗血小板治疗,所有这些都可能是 SRMB 的危险因素。然而,尚无研究评估 aSAH 患者的 SRMB。本研究的目的是确定 aSAH 患者中 SRMB 的发生率,评估抑酸对 SRMB 的影响,并确定 SRMB 的具体危险因素。
这是一项在 17 个中心进行的多中心、回顾性、观察性研究。每个中心回顾了最近最多 50 例 aSAH 患者的情况。排除住院时间(LOS)<48 小时或入院时存在活动性胃肠道(GI)出血的患者。收集了与人口统计学、aSAH 严重程度、GI 出血、提供 SRMB 预防措施、不良事件、重症监护病房(ICU)和住院 LOS 相关的变量,时间范围为入院后的前 21 天或直至出院,以先发生者为准。采用描述性统计分析数据。采用多变量逻辑回归模型检查特定危险因素与 aSAH 患者临床重要性 GI 出血发生率之间的关系。
共纳入 627 例患者。临床重要性 GI 出血的总发生率为 4.9%。在发生临床重要性 GI 出血的患者中,19 例(61%)在出现 GI 出血之前接受了药物预防,而 12 例(39%)在 GI 出血发生时未接受药物预防。接受抑酸剂治疗的患者发生 GI 出血的可能性低于在出血前未接受药物预防的患者(OR 0.39,95%CI 0.18-0.83)。多变量回归分析确定任何颅内压升高、肌酐清除率<60ml/min 和脑血管痉挛的发生均为与 GI 出血相关的特定危险因素。脑血管痉挛以前从未被描述为 GI 出血的危险因素(OR 2.5,95%CI 1.09-5.79)。
aSAH 患者中发生临床重要性 GI 出血的比例为 4.9%,与一般重症监护人群相似。与 GI 出血相关的危险因素包括机械通气时间延长(>48 小时)、肌酐清除率<60ml/min、凝血功能障碍、颅内压升高和脑血管痉挛。需要进一步的前瞻性研究来证实这一观察结果在该患者人群中的适用性。